Annual CFF
$4.65 M
+$4.67 M+20321.74%
31 December 2023
Summary:
Moleculin Biotech annual cash flow from financing activities is currently $4.65 million, with the most recent change of +$4.67 million (+20321.74%) on 31 December 2023. During the last 3 years, it has fallen by -$17.90 million (-79.37%). MBRX annual CFF is now -93.78% below its all-time high of $74.72 million, reached on 31 December 2021.MBRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$4.66 M
+$4.68 M+18736.00%
30 September 2024
Summary:
Moleculin Biotech quarterly cash flow from financing activities is currently $4.66 million, with the most recent change of +$4.68 million (+18736.00%) on 30 September 2024. Over the past year, it has increased by +$4.66 million (+116575.00%). MBRX quarterly CFF is now -93.77% below its all-time high of $74.75 million, reached on 31 March 2021.MBRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$9.10 M
+$4.66 M+105.12%
30 September 2024
Summary:
Moleculin Biotech TTM cash flow from financing activities is currently $9.10 million, with the most recent change of +$4.66 million (+105.12%) on 30 September 2024. Over the past year, it has increased by +$8.91 million (+4791.94%). MBRX TTM CFF is now -90.11% below its all-time high of $92.01 million, reached on 31 March 2021.MBRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MBRX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10000.0% | +10000.0% | +4791.9% |
| 3 y3 years | -79.4% | +10000.0% | -88.7% |
| 5 y5 years | -61.4% | +8859.6% | -59.8% |
MBRX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -93.8% | >+9999.0% | at high | >+9999.0% | -88.7% | >+9999.0% |
| 5 y | 5 years | -93.8% | >+9999.0% | -93.8% | >+9999.0% | -90.1% | >+9999.0% |
| alltime | all time | -93.8% | >+9999.0% | -93.8% | >+9999.0% | -90.1% | >+9999.0% |
Moleculin Biotech Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $4.66 M(<-9900.0%) | $9.10 M(+105.1%) |
| June 2024 | - | -$25.00 K(<-9900.0%) | $4.44 M(-1.6%) |
| Mar 2024 | - | $0.00(-100.0%) | $4.51 M(-3.0%) |
| Dec 2023 | $4.65 M(<-9900.0%) | $4.46 M(<-9900.0%) | $4.65 M(+2400.5%) |
| Sept 2023 | - | -$4000.00(-108.2%) | $186.00 K(+3.9%) |
| June 2023 | - | $49.00 K(-65.2%) | $179.00 K(+51.7%) |
| Mar 2023 | - | $141.00 K(>+9900.0%) | $118.00 K(-613.0%) |
| Dec 2022 | -$23.00 K(-100.0%) | $0.00(-100.0%) | -$23.00 K(0.0%) |
| Sept 2022 | - | -$11.00 K(-8.3%) | -$23.00 K(-36.1%) |
| June 2022 | - | -$12.00 K(<-9900.0%) | -$36.00 K(+50.0%) |
| Mar 2022 | - | $0.00(0.0%) | -$24.00 K(-100.0%) |
| Dec 2021 | $74.72 M(+231.4%) | $0.00(-100.0%) | $74.72 M(-6.8%) |
| Sept 2021 | - | -$24.00 K(<-9900.0%) | $80.21 M(-2.2%) |
| June 2021 | - | $0.00(-100.0%) | $81.99 M(-10.9%) |
| Mar 2021 | - | $74.75 M(+1263.0%) | $92.01 M(+308.0%) |
| Dec 2020 | $22.55 M | $5.48 M(+211.2%) | $22.55 M(+32.1%) |
| Sept 2020 | - | $1.76 M(-82.4%) | $17.07 M(+11.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2020 | - | $10.01 M(+89.2%) | $15.36 M(-25.5%) |
| Mar 2020 | - | $5.29 M(>+9900.0%) | $20.62 M(-1.1%) |
| Dec 2019 | $20.85 M(+73.1%) | $0.00(-100.0%) | $20.85 M(-7.8%) |
| Sept 2019 | - | $52.00 K(-99.7%) | $22.61 M(+0.2%) |
| June 2019 | - | $15.28 M(+176.8%) | $22.56 M(+141.3%) |
| Mar 2019 | - | $5.52 M(+213.5%) | $9.35 M(-22.4%) |
| Dec 2018 | $12.04 M(+19.7%) | $1.76 M(>+9900.0%) | $12.04 M(+3.2%) |
| Sept 2018 | - | $0.00(-100.0%) | $11.67 M(-8.5%) |
| June 2018 | - | $2.07 M(-74.8%) | $12.75 M(-2.0%) |
| Mar 2018 | - | $8.21 M(+493.6%) | $13.01 M(+29.3%) |
| Dec 2017 | $10.06 M(+13.5%) | $1.38 M(+27.8%) | $10.06 M(+15.9%) |
| Sept 2017 | - | $1.08 M(-53.5%) | $8.68 M(+14.3%) |
| June 2017 | - | $2.33 M(-55.8%) | $7.59 M(-44.1%) |
| Mar 2017 | - | $5.26 M(>+9900.0%) | $13.58 M(+53.2%) |
| Dec 2016 | $8.87 M | $3000.00(>+9900.0%) | $8.87 M(+0.0%) |
| Sept 2016 | - | $0.00(-100.0%) | $8.86 M(0.0%) |
| June 2016 | - | $8.31 M(+1405.4%) | $8.86 M(+1505.4%) |
| Mar 2016 | - | $552.00 K | $552.00 K |
FAQ
- What is Moleculin Biotech annual cash flow from financing activities?
- What is the all time high annual CFF for Moleculin Biotech?
- What is Moleculin Biotech annual CFF year-on-year change?
- What is Moleculin Biotech quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Moleculin Biotech?
- What is Moleculin Biotech quarterly CFF year-on-year change?
- What is Moleculin Biotech TTM cash flow from financing activities?
- What is the all time high TTM CFF for Moleculin Biotech?
- What is Moleculin Biotech TTM CFF year-on-year change?
What is Moleculin Biotech annual cash flow from financing activities?
The current annual CFF of MBRX is $4.65 M
What is the all time high annual CFF for Moleculin Biotech?
Moleculin Biotech all-time high annual cash flow from financing activities is $74.72 M
What is Moleculin Biotech annual CFF year-on-year change?
Over the past year, MBRX annual cash flow from financing activities has changed by +$4.67 M (+20321.74%)
What is Moleculin Biotech quarterly cash flow from financing activities?
The current quarterly CFF of MBRX is $4.66 M
What is the all time high quarterly CFF for Moleculin Biotech?
Moleculin Biotech all-time high quarterly cash flow from financing activities is $74.75 M
What is Moleculin Biotech quarterly CFF year-on-year change?
Over the past year, MBRX quarterly cash flow from financing activities has changed by +$4.66 M (+116575.00%)
What is Moleculin Biotech TTM cash flow from financing activities?
The current TTM CFF of MBRX is $9.10 M
What is the all time high TTM CFF for Moleculin Biotech?
Moleculin Biotech all-time high TTM cash flow from financing activities is $92.01 M
What is Moleculin Biotech TTM CFF year-on-year change?
Over the past year, MBRX TTM cash flow from financing activities has changed by +$8.91 M (+4791.94%)